PYCR1 Human Pre-designed siRNA Set A contains three designed siRNAs for PYCR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for PYCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYGB Human Pre-designed siRNA Set A contains three designed siRNAs for PYGB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYGL Human Pre-designed siRNA Set A contains three designed siRNAs for PYGL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYGM Human Pre-designed siRNA Set A contains three designed siRNAs for PYGM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYGO1 Human Pre-designed siRNA Set A contains three designed siRNAs for PYGO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYGO2 Human Pre-designed siRNA Set A contains three designed siRNAs for PYGO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYHIN1 Human Pre-designed siRNA Set A contains three designed siRNAs for PYHIN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM[1].

Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM[1].

Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM[1].

Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM[1].

Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM[1].

PYM1 Human Pre-designed siRNA Set A contains three designed siRNAs for PYM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pyraclostrobin (Standard) is the analytical standard of Pyraclostrobin. This product is intended for research and analytical applications. Pyraclostrobin is a highly effective and broad-spectrum strobilurin fungicide. Pyraclostrobin can induce oxidative DNA damage, mitochondrial dysfunction and autophagy through the activation of AMPK/mTOR signaling. Pyraclostrobin can be used to control crop diseases[1][2][3].

Pyranine (hydrate) (HPTS (hydrate); Solvent Green 7 (hydrate)) is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide […]

Pyrantel (pamoate) (Standard) is the analytical standard of Pyrantel (pamoate). This product is intended for research and analytical applications. Pyrantel pamoate (Pyrantel embonate) is an orally active anthelmintic and an agonist of the nicotinic acetylcholine receptor (nAChR). Pyrantel pamoate can cause spasmodic muscle paralysis in parasites. Pyrantel pamoate can be used in the study of […]

Pyrazinamide-13C,15N is 15N and 13C labeled Pyrazinamide (HY-B0271). Pyrazinamide (Pyrazinecarboxamide; Pyrazinoic acid amide) is a potent and orally active antitubercular antibiotic. Pyrazinamide is a proagent that is converted to the active form pyrazinoic acid (POA) by PZase/nicotinamidase encoded by the pncA gene in M. tuberculosis.

Pyrazinamide-BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Pyrazinamide (HY-B0271) and BSA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

Pyrazinamide-KLH is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Pyrazinamide (HY-B0271) and KLH. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

Pyrenocine A is an acyl phytotoxin isolated from plant pathogenic fungi[1].

PYRIB-SO 2 is a potent antimitotic agent. PYRIB-SO 2 shows antiproliferative activity and induces cell cycle arrest at G2/M phase. PYRIB-SO 2 reduces and disruptes microtubule structures. PYRIB-SO 2 binds to the colchicine-binding site (C-BS) of α, β-tubulin[1].

Pyridomycin (Erizomycin) is a selective and low cytotoxic inhibitor of Mycobacterium tuberculosis that effectively targets InhA. Pyrdomycin is also an antibiotic that can be obtained from metabolites of Dactylosporangium fulvum. Pyrdomycin can be used in the study of bacterial infections such as tuberculosis[1][2].

PYROXD1 Human Pre-designed siRNA Set A contains three designed siRNAs for PYROXD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pyrrolidine ricinoleamide ((R)-5d) is a fatty acid amide that exhibits effective antiproliferative activity against a series of cancer cells, including human glioma U251 cells. Pyrrolidine ricinoleamide can be used in cancer research[1].

Pyrroline-5-carboxylate sodium participates in amino acid metabolism in organisms and is an intermediate product of proline biosynthesis and catabolism. During pathogen infection and abiotic stress[1]

Pyrroline-5-carboxylate sodium participates in amino acid metabolism in organisms and is an intermediate product of proline biosynthesis and catabolism. During pathogen infection and abiotic stress[1]

Pyrroline-5-carboxylate sodium participates in amino acid metabolism in organisms and is an intermediate product of proline biosynthesis and catabolism. During pathogen infection and abiotic stress[1]

Pyrroline-5-carboxylate sodium participates in amino acid metabolism in organisms and is an intermediate product of proline biosynthesis and catabolism. During pathogen infection and abiotic stress[1]

Pyrroline-5-carboxylate sodium participates in amino acid metabolism in organisms and is an intermediate product of proline biosynthesis and catabolism. During pathogen infection and abiotic stress[1]

PYURF Human Pre-designed siRNA Set A contains three designed siRNAs for PYURF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PYY Human Pre-designed siRNA Set A contains three designed siRNAs for PYY gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PZ-1922 free base is a BBB-penetrable 5-HT6R/5-HT3R antagonist (Ki: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 free base reversibly inhibits MAO-B (pIC50: 8.93). PZ-1922 free base reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 free base prevents Aβ-induced memory decline in the T-maze test[1].

PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to α6β3γ2. PZ-II-029 shows anti-migraine effects[1].

PZP Human Pre-designed siRNA Set A contains three designed siRNAs for PZP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

QC-182 is a potent PROTAC degrader of p300/CBP. QC-182 reduces p300 protein in the SK-HEP-1 cells (DC50 = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC50 values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC)[1].

QDPR Human Pre-designed siRNA Set A contains three designed siRNAs for QDPR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

QKI Human Pre-designed siRNA Set A contains three designed siRNAs for QKI gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

QL47B TFA, a biotinylated analogue of QL47 (HY-80003), is a potent inhibitor of BTK, with an IC50 value of 1.3 μM. QL47B TFA has anti-tumor activity[1].

QM-FN-SO3 ammonium is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO3 ammonium can be used for in vivo detection of Aβ plaques. QM-FN-SO3 ammonium has ultra-high S/N ratio, binding affinity, and high-performance NIR emission[1].

QO-40 is a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative and an activator of the voltage-gated M-type potassium channel KCNQ encoded by the KCNQ2/3 gene (EC50: 1.25 μM)[1][2].

QO-40 is a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative and an activator of the voltage-gated M-type potassium channel KCNQ encoded by the KCNQ2/3 gene (EC50: 1.25 μM)[1][2].

QO-40 is a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative and an activator of the voltage-gated M-type potassium channel KCNQ encoded by the KCNQ2/3 gene (EC50: 1.25 μM)[1][2].

QO-40 is a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative and an activator of the voltage-gated M-type potassium channel KCNQ encoded by the KCNQ2/3 gene (EC50: 1.25 μM)[1][2].

QO-40 is a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative and an activator of the voltage-gated M-type potassium channel KCNQ encoded by the KCNQ2/3 gene (EC50: 1.25 μM)[1][2].

QPCT Human Pre-designed siRNA Set A contains three designed siRNAs for QPCT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.